A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration

Current SARS-CoV-2 Omicron subvariants impose a heavy burden on global health systems by evading immunity from most developed neutralizing antibodies and vaccines. Here, we identified a nanobody (aSA3) that strongly cross-reacts with the receptor binding domain (RBD) of both SARS-CoV-1 and wild-type...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Huan, Zhang, Xinghai, Zeng, Weihong, Zhou, Junhui, Chi, Xiangyang, Chen, Shaohong, Zheng, Peiyi, Wang, Meihua, Wu, Yan, Zhao, Dan, Gong, Fanwu, Lin, Haofeng, Sun, Hancong, Yu, Changming, Shi, Zhengli, Hu, Xiaowen, Zhang, Huajun, Jin, Tengchuan, Chiu, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734137/
https://www.ncbi.nlm.nih.gov/pubmed/36494344
http://dx.doi.org/10.1038/s41421-022-00497-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734137/
https://www.ncbi.nlm.nih.gov/pubmed/36494344
http://dx.doi.org/10.1038/s41421-022-00497-w

Ejemplares similares